Skip to main content


Latest articles

10-08-2020 | Oncology | News | Article

Considerations for conducting phase 1 trials in COVID-19 era proposed

A French team has put forward preliminary guidance for conducting phase 1 oncology clinical trials during the COVID-19 pandemic, including specific precautions for managing any participants with SARS-CoV-2.

07-08-2020 | Oncology | News | Article

Neoadjuvant chemohormonal therapy not yet encouraged for localized prostate cancer

The use of chemohormonal therapy before radical prostatectomy does not significantly improve 3-year biochemical recurrence-free survival in men with localized, high-risk prostate cancer, phase 3 trial findings suggest.

06-08-2020 | Oncology | News | Article

COVID-19 treatments show minimal benefit in infected cancer patients

Results from the COVID-19 and Cancer Consortium show that a variety of treatments for COVID-19 have no significant positive impact on 30-day mortality in patients with invasive cancer.

06-08-2020 | Oncology | News | Article

Late relapse in ER-positive, early breast cancer influenced by genetic variants

A post-hoc analysis of the BIG 1–98 trial has identified genetic variants associated with the risk for recurrence after 5 years of adjuvant endocrine therapy in postmenopausal women with estrogen receptor-positive, HER2-negative, early-stage breast cancer.

05-08-2020 | Oncology | News | Article

Neratinib boosts PFS in pretreated advanced HER2-positive breast cancer

Supplementing capecitabine with neratinib instead of lapatinib is associated with a significant improvement in the progression-free survival of previously treated patients with metastatic HER2-positive breast cancer, shows the phase 3 NALA trial.

03-08-2020 | Oncology | News | Article

Cancer patients with asymptomatic COVID-19 characterized

A Chinese report has shed light on the characteristics of cancer patients with asymptomatic SARS-CoV-2 infection.

Image Credits